#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Autoimmune demyelinating disease Human papilloma virus immunisation Activated PI3 kinase delta syndrome Thalassaemia beta Vitamin B12 deficiency Small intestine neuroendocrine tumour Haemophilia A without inhibitors Atypical haemolytic uraemic syndrome Biliary neoplasm Carcinoid syndrome Peritoneal neoplasm Primary myelofibrosis Eosinophilic oesophagitis Neurodegenerative disorder Acute myeloid leukaemia (in remission) More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis – Diagnostics Usher’s syndrome – Life with Disease Hereditary angioedema – Basic Information Gaucher’s disease type III – Treatment Prolymphocytic leukaemia Bronchopulmonary dysplasia – Treatment Advanced systemic mastocytosis – Trials in Disease Cholangitis sclerosing – Treatment Niemann-Pick disease Mucous membrane pemphigoid – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vedolizumab Atazanavir Pivmecillinam Hydrochloride Mrna-3210 Astegolimab Plerixafor Omp65 Bms-986340 Mebendazole Fluorouracil Sodium Cyanocobalamin Ofloxacin Pioglitazone Hydrochloride Calcifediol Ads-013 Nanatinostat Blu-451 NIZUBAGLUSTAT Dolutegravir Crovalimab More therapies…

    Learn about Your Condition

    Nephrolithiasis Malignant melanoma stage III Proteus syndrome Hyperglycaemia Antithrombin III deficiency Restless legs syndrome Alcohol use disorder Crohn's disease Craniosynostosis Peritoneal sarcoma Infection Acute on chronic liver failure Drug dependence Nocturia Microvillous inclusion disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Fabry’s disease

  • Title: Evaluating low-dose prednisone with standard therapy to improve heart function in patients with cardiac manifestations of Fabry disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Prednisone
    Poland

  • Study on the Safety and Effects of Pegunigalsidase Alfa for Children and Adolescents with Fabry Disease

    Recruiting

    4 1 1
    Investigated Drugs:
    • Pegunigalsidase Alfa
    Austria France Norway Spain

  • Efficacy and Safety of Lucerastat in Treatment‑Naïve Adult Male Patients with Fabry Disease

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Fabry’s disease
    Investigated Drugs:
    • Lucerastat
    France Germany

  • A Study of Migalastat Safety and Effects in Children Aged 2 to 12 Years with Fabry Disease and Suitable Gene Changes

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Fabry’s disease
    Belgium Germany Spain

  • Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Fabry’s disease
    Investigated Drugs:
    • AGALSIDASE BETA
    • Migalastat
    • Venglustat
    Austria Czechia Denmark France Germany Greece +5

  • Long-Term Safety Study of ST-920 Gene Therapy for Patients with Fabry Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Fabry’s disease
    Investigated Drugs:
    • Isaralgagene Civaparvovec
    Germany
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!